{"title":"错误部","authors":"","doi":"10.1016/s0140-6736(25)00621-x","DOIUrl":null,"url":null,"abstract":"<em>Ferrante M, D’Haens G, Jairath V, et al. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.</em> Lancet <em>2024; <strong>404:</strong> 2423–36</em>—In this Article, Massimo Claudio Fantini's full name should have been included in the VIVID Study Group; the first column of table 1 should have been “median C-reactive protein” and “median faecal calprotectin” as opposed to mean; and two people, Minhu Chen and Britta Siegmund, should have been mentioned in the VIVID-1 Steering Committee list in the appendix. These corrections have been made to the online version as of April 10, 2025.","PeriodicalId":22898,"journal":{"name":"The Lancet","volume":"108 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Department of Error\",\"authors\":\"\",\"doi\":\"10.1016/s0140-6736(25)00621-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<em>Ferrante M, D’Haens G, Jairath V, et al. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.</em> Lancet <em>2024; <strong>404:</strong> 2423–36</em>—In this Article, Massimo Claudio Fantini's full name should have been included in the VIVID Study Group; the first column of table 1 should have been “median C-reactive protein” and “median faecal calprotectin” as opposed to mean; and two people, Minhu Chen and Britta Siegmund, should have been mentioned in the VIVID-1 Steering Committee list in the appendix. These corrections have been made to the online version as of April 10, 2025.\",\"PeriodicalId\":22898,\"journal\":{\"name\":\"The Lancet\",\"volume\":\"108 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-04-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Lancet\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/s0140-6736(25)00621-x\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Lancet","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s0140-6736(25)00621-x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Ferrante M, D’Haens G, Jairath V, et al. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study. Lancet 2024; 404: 2423–36—In this Article, Massimo Claudio Fantini's full name should have been included in the VIVID Study Group; the first column of table 1 should have been “median C-reactive protein” and “median faecal calprotectin” as opposed to mean; and two people, Minhu Chen and Britta Siegmund, should have been mentioned in the VIVID-1 Steering Committee list in the appendix. These corrections have been made to the online version as of April 10, 2025.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
